Article

StratosPHere 2: A response-adaptive randomised placebo-controlled Phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2

2023-10-11

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> • Pulmonary arterial hypertension is a life-threatening progressive disorder characterised by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery). Although treatable, there is no known cure for this rare disorder, and its exact cause is unknown. Mutations in the bone morphogenetic protein receptor type-2 (BMPR2) are the most common...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c1a85454-4c2c-52ef-b955-38ea6b8c6aec
DOI: 10.21203/rs.3.rs-3392621/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

StratosPHere 2: A response-adaptive randomised placebo-controlled Phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2DOI 10.21203/rs.3.rs-3392621/v1Read

StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2.Semantic proximity Read

Recent advances in pulmonary arterial hypertensionSemantic proximity Read

BMPR-II biomarkers for testing therapeutic efficacy in pulmonary arterial hypertension –the StratosPHere 1 studySemantic proximity Read

Pulmonary Hypertension: Pharmacological and Non-Pharmacological TherapiesSemantic proximity Read

[Pulmonary (Arterial) Hypertension].Semantic proximity Read

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.Semantic proximity Read

Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR).Semantic proximity Read

iPSC modeling of pulmonary arterial hypertension to uncover pathomechanisms and unrecognized modes of action of sotaterceptSemantic proximity Read

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.Semantic proximity Read

Primary pulmonary hypertension: molecular basis and potential for therapy.Semantic proximity Read

Developments in therapeutics for pulmonary arterial hypertension.Semantic proximity Read

Management of Pulmonary Arterial Hypertension. Current Strategies and Future ProspectsSemantic proximity Read